Aprea Therapeutics secured funding of USD 34 million and FDA IND approval for APR-1051 to initiate the first clinical study.
Amount Raised
$34 Million
Round Type
Funding Round
DoylestownBiotechnologyHealth CareScience And EngineeringTherapeuticsInvestors
Description
Aprea Therapeutics, a portfolio company of Karolinska Development, has received FDA IND approval for the drug candidate APR-1051 and secured funding up to USD 34 million through a financing round led by Sphera Healthcare. With the approval and financing, the company will commence the first clinical study with APR-1051 to evaluate its therapeutic activity in patients with a focus on cancer forms that overexpress Cyclin E.
Quick answer
Aprea Therapeutics raised $34 Million in a Funding Round round, dated March 18, 2024. Investors: Stonepine Capital Management, Exome Asset Management, Dafna Capital Management, Nantahala Capital and Sphera Healthcare. Aprea Therapeutics is based in Doylestown, Pennsylvania, United States.
- How much did Aprea Therapeutics raise?
- Aprea Therapeutics raised $34 Million in a Funding Round round on March 18, 2024.
- Who invested in Aprea Therapeutics?
- Stonepine Capital Management, Exome Asset Management, Dafna Capital Management, Nantahala Capital and Sphera Healthcare are named as investors in this round.
- What does Aprea Therapeutics do?
- Aprea Therapeutics (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality.
- Where is Aprea Therapeutics based and how big is it?
- Aprea Therapeutics is based in Doylestown, Pennsylvania, United States.
- Who are the decision-makers at Aprea Therapeutics?
- Fundz holds 1 contact at Aprea Therapeutics, including the President & CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Therapeutics around the same time
Companies in the same sectors as Aprea Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Enliven Therapeutics raised $90M on March 21, 2024.
- Enliven Therapeutics raised $90M (Post-IPO Equity) on March 20, 2024.
- MAIA Biotechnology raised $2.9M (Seed) on March 11, 2024.
- Novocure raised $400M (Debt Financing) on May 2, 2024.
- Delphia Therapeutics raised $67M (Series A) on May 2, 2024.
- Scipher Medicine raised $25M on May 2, 2024.
Who to call at Aprea Therapeutics, and when
A new round usually means Aprea Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Aprea Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aprea Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aprea Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aprea Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Aprea Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.